Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIF - Post Discussion

IMV Inc > Hurdle rate bladder and MSS High are super good
View:
Post by Biotech010 on Sep 24, 2021 6:59am

Hurdle rate bladder and MSS High are super good

Wells Fargo analyst Nick Abbott put a $14 PT on the stock. You want to know why....????


The basket trial results from the KEYTRUDA combination data in MSS-high solid tumors and  bladder cancer are impressive. The so called hurdle rate... when to go / stop a trial... wasn't published in the press release. But this info was in the Wells Fargo report.

And the results were super good and way beyond what KEYTRUDA achieved in monotherapy. WIth this data coming up in Q4 2021... we should really see upward momentum for the stock.

Andrew en Jeremy are doing great work communicating and telling the IMV story.

 
Comment by alphaseeking001 on Oct 12, 2021 6:10pm
Anyone have access to the Wells Fargo note?  If so, could they post it up here? Thanks quote=Biotech010] Wells Fargo analyst Nick Abbott put a $14 PT on the stock. You want to know why....???? The basket trial results from the KEYTRUDA combination data in MSS-high solid tumors and  bladder cancer are impressive. The so called hurdle rate... when to go / stop a trial... wasn& ...more  
Comment by Hideaway on Oct 15, 2021 10:17am
Alpha,I would also appreciate more details from the WF report.Not sure I understand how this WF analyst could get access to this information as it appears to be material matters that the Company would have to officially release.It is certainly news that should propel the SP northward if subistanted.One would think that such a leak would have an immediate and positive effect on the shares but this ...more  
Comment by alphaseeking001 on Oct 16, 2021 4:52pm
Agreed Hideaway.  My feelings exactly.  That's why I'd like to see the report.  I bought back a bit more the other day.  I feel that any good news could bump the stock a bit.  Even an announcement of a  new replacement CEO... providing they have solid experience.  I'm a bit surprised they haven't hired someone yet.  I'd rather they find ...more  
Comment by Biotech010 on Oct 21, 2021 4:45pm
8 weeks to deliver some big PR's. I really look forward to the basket trial. In the latest presentation it says Bladder and MSI "Promising preliminary results"  I spoke to some European investors and they are buying on the dip. The next 6-9 months should be life changing for IMV. I really urge investors to contact the company if they have any questions.  Despite the ...more  
Comment by Lambom on Oct 22, 2021 10:53am
Why contact the company? Marc's responses are dull , generic , does not answer questions lol heck he does not even answer his phones. At this point its just a roll of the dice. 
Comment by Biotech010 on Oct 22, 2021 2:11pm
try Pierre, always quick and he does has something to say;) 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities